VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...
The issues are complex, with no single causative factor. Yet central to these changes is the role of volition – human agency. Women everywhere have made and are making their own decisions about ...
Saber CEO Matthew Karch, whose company used to be part of Embracer alongside Volition, explains what happened to the defunct ...
VolitionRx (VNRX) announces the results of a study which shows that an automated Nu.Q Cancer immunoassay test in development detected a range ...
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 ...
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback